Authorized purpose: Concurrent CAD/CADx aid for interpreting physicians reading compatible DBT exams to detect soft-tissue densities and calcifications for physician confirmation or dismissal.
Clinical role
Concurrent detection, localization, and characterization aid; physician review and confirmation or dismissal remain required.
Images and patients
Mammography/DBT · Breast.
Key limitation
Keep in mind: Concurrent adjunctive use with compatible DBT systems is required; interpreting physicians confirm or dismiss marked findings. Certainty of Finding and Case Scores are algorithm confidence scores, and the packet does not establish them as calibrated probabilities or a replacement for physician review.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Concurrent CAD/CADx aid for interpreting physicians reading compatible DBT exams to detect soft-tissue densities and calcifications for physician confirmation or dismissal.
Which images or clinical context are in scope?Modality: Mammography/DBT Anatomy or clinical context: Breast. Input: 3D DBT exams from compatible DBT systems; prior exams may be processed when available. The standalone test used Hologic DBT exams, and the submission lists Hologic, GE, and Siemens compatible systems under its supported-system/PCCP discussion.
Who uses it?Intended users: Interpreting physicians.
What does the software produce?Output: Overlay marks on tomosynthesis images, a maximum of three marks per view, Certainty of Finding scores from 0%-100% for detected findings, Case Scores from 0%-100% for cases, and softcopy-workstation display; prior-exam processing is supported when available.
What is its most important limitation?Key limitation: Concurrent adjunctive use with compatible DBT systems is required; interpreting physicians confirm or dismiss marked findings. Certainty of Finding and Case Scores are algorithm confidence scores, and the packet does not establish them as calibrated probabilities or a replacement for physician review.
Clinical takeaway. Clinical role: Concurrent CAD/CADx aid for interpreting physicians reading compatible DBT exams to detect soft-tissue densities and calcifications for physician confirmation or dismissal.
Evidence takeaway. Evidence from the reviewed source record: FDA K240417 reports a primary non-inferiority/paired comparison and standalone performance results in the same independent-data discussion. The standalone dataset contains 952 cases, including 251 biopsy-proven cancer cases with 256 malignant lesions and 701 non-cancer cases. V4.0 using priors reported sensitivity 0.9004, specificity 0.6205, and AUC 0.8753; V4.0 without priors reported 0.9004, 0.5863, and 0.8714; the predicate V3.0 reported 0.8725, 0.5278, and 0.8230. The data were retrospectively collected from U.S. image-acquisition sites and used established clinical reference standards.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Concurrent CAD/CADx aid for interpreting physicians reading compatible DBT exams to detect soft-tissue densities and calcifications for physician confirmation or dismissal.
3D DBT exams from compatible DBT systems; prior exams may be processed when available. The standalone test used Hologic DBT exams, and the submission lists Hologic, GE, and Siemens compatible systems under its supported-system/PCCP discussion.
Overlay marks on tomosynthesis images, a maximum of three marks per view, Certainty of Finding scores from 0%-100% for detected findings, Case Scores from 0%-100% for cases, and softcopy-workstation display; prior-exam processing is supported when available.
Breast-imaging and DBT reading workflow using compatible DBT acquisition systems; the FDA packet does not specify a facility type or an intended age range.
Concurrent adjunctive use with compatible DBT systems is required; interpreting physicians confirm or dismiss marked findings. Certainty of Finding and Case Scores are algorithm confidence scores, and the packet does not establish them as calibrated probabilities or a replacement for physician review.
FDA K240417 reports a primary non-inferiority/paired comparison and standalone performance results in the same independent-data discussion. The standalone dataset contains 952 cases, including 251 biopsy-proven cancer cases with 256 malignant lesions and 701 non-cancer cases. V4.0 using priors reported sensitivity 0.9004, specificity 0.6205, and AUC 0.8753; V4.0 without priors reported 0.9004, 0.5863, and 0.8714; the predicate V3.0 reported 0.8725, 0.5278, and 0.8230. The data were retrospectively collected from U.S. image-acquisition sites and used established clinical reference standards.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
FDA K240417 reports a primary non-inferiority/paired comparison and standalone performance results in the same independent-data discussion. The standalone dataset contains 952 cases, including 251 biopsy-proven cancer cases with 256 malignant lesions and 701 non-cancer cases. V4.0 using priors reported sensitivity 0.9004, specificity 0.6205, and AUC 0.8753; V4.0 without priors reported 0.9004, 0.5863, and 0.8714; the predicate V3.0 reported 0.8725, 0.5278, and 0.8230. The data were retrospectively collected from U.S. image-acquisition sites and used established clinical reference standards.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
ProFound Detection (V4.0) regulatory performance study summary
DesignStand-Alone Performance
PopulationPopulation described in the exact-submission ACR model card
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K240417
Samplen=952
IndependenceIndependence not established
K240417
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K240417. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: 3D DBT exams from compatible DBT systems; prior exams may be processed when available. The standalone test used Hologic DBT exams, and the submission lists Hologic, GE, and Siemens compatible systems under its supported-system/PCCP discussion.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: Softcopy-workstation display with compatible DBT acquisition systems is described, including a predetermined change-control plan for additional systems. A specific PACS, RIS, EHR, or routing interface is not established by the packet.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Unresolved route: Not established for the exact route.
Scope: Exact FDA submission. The exact FDA decision document was reviewed on 2026-11-14 and does not state where the subject device's software runs or how it is hosted. Confirm the deployment model, hosting, data flow, and current commercial configuration with the vendor.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-11-14 ·
Returned objects
Source context, not route validation: Overlay marks on tomosynthesis images, a maximum of three marks per view, Certainty of Finding scores from 0%-100% for detected findings, Case Scores from 0%-100% for cases, and softcopy-workstation display; prior-exam processing is supported when available.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Overlay marks on tomosynthesis images, a maximum of three marks per view, Certainty of Finding scores from 0%-100% for detected findings, Case Scores from 0%-100% for cases, and softcopy-workstation display; prior-exam processing is supported when available.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
Softcopy-workstation display with compatible DBT acquisition systems is described, including a predetermined change-control plan for additional systems. A specific PACS, RIS, EHR, or routing interface is not established by the packet.
iCAD's coordinated vulnerability disclosure statement commits to vulnerability intake via support@icadmed.com, confidential report handling, an evaluation response with an expected resolution date based on severity, progress updates to the reporter, and a safe-harbor commitment not to take legal action against reporters who follow the policy.
Vendor-wide
Checked 2026-10-27
Vendor statement on the iCAD owning domain (icadmed.com); the page banner notes iCAD is now part of DeepHealth, but the statement is iCAD's own product/system disclosure policy. No certification or audit report was read; exact-release scope is not established. Applicant name variant 'iCAD, Inc.' is bridged to iCAD, Inc. via the identical distinctive name and iCAD product naming.
iCAD's coordinated vulnerability disclosure statement states confidential intake, an evaluation response with a severity-based expected resolution date, and progress updates to the reporter.
Vendor-wide
Checked 2026-10-27
Vendor statement, not an attestation. The statement names iCAD generally and does not scope these commitments to any specific product release; exact-release scope is not established.
ACR AI Central provides an exact-submission model card for ProFound Detection (V4.0); FDA labeling remains controlling for clinical use, limitations, and performance.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
21Fields reviewed
9Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission
No public price or quote for the exact K240417 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Deployment: Not publicly available - checked 2026-11-14 - Exact FDA submission
The exact FDA decision document was reviewed on 2026-11-14 and does not state where the subject device's software runs or how it is hosted. Confirm the deployment model, hosting, data flow, and current commercial configuration with the vendor.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-08 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Authorized purpose: Lunit INSIGHT MMG v1.1.10 aids physicians in detection, localization and characterization of suspicious breast-cancer areas on female screening mammograms from compatible FFDM systems, viewed after the physician's initial read as an adjunct to complete clinical interpretation.
Authorized purpose: Concurrent CADe/x aid for interpreting physicians to detect and characterize breast-cancer-suspicious lesions in screening DBT exams from compatible systems, marking soft-tissue lesions and calcifications with abnormality scores.
Authorized purpose: Genius AI Detection 2.0 analyzes compatible digital breast tomosynthesis exams to identify and mark soft-tissue densities (masses, architectural distortions, asymmetries) and calcifications, providing lesion location/outline, confidence or Certainty of Findings, and a case score for concurrent review; the interpreting physician confirms or dismisses findings.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.